All this evidence provides a high level of confidence that the clinical performance of plasma RAS testing using OncoBEAM RAS is comparable with FFPE tissue testing and can be useful in a clinical setting to select advanced CRC patients for anti-EGFR therapy. This evidence concerns the gene EGFR and colorectal carcinoma.